Welcome to our dedicated page for Clearpoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on Clearpoint Neuro stock.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) is a medical device company focused on device, cell, and gene therapy-enabling technologies for precise navigation to the brain and spine. This news page aggregates company-issued updates and market-moving announcements related to ClearPoint Neuro’s neurosurgical navigation systems, laser therapy platforms, intracranial fluid management technologies, and central nervous system drug delivery services.
Readers can follow earnings and financial updates, such as preliminary unaudited revenue results and quarterly reports furnished via Form 8-K, which outline trends in biologics and drug delivery revenue, neurosurgery navigation and therapy revenue, and capital equipment and software sales. News items also cover strategic transactions, including the completed acquisition of IRRAS Holdings, Inc., which adds the IRRAflow active fluid-exchange system and expands ClearPoint Neuro’s presence in neurocritical care and intracranial bleeding management.
ClearPoint Neuro’s news flow frequently highlights regulatory milestones like FDA 510(k) clearances, including expanded MRI compatibility for the ClearPoint Prism Neuro Laser Therapy System, and international regulatory approvals that extend product use to additional countries. The company also reports on clinical and scientific developments, such as Phase I–II study results in glioblastoma and grade 4 astrocytoma using ClearPoint Prism, as well as the development and demonstration of its proprietary Robotic Neuro-Navigation System.
Investors and observers can also track partnership and conference activity, including updates on more than 60 active biopharma partners, participation in global healthcare conferences, and progress at ClearPoint Advanced Laboratories. Bookmark this page to review historical and ongoing CLPT news related to neurosurgical devices, therapy delivery platforms, and the company’s role in enabling cell and gene therapy programs.
ClearPoint Neuro has announced the first human cases using its SmartFrame Array Neuro Navigation System, aiming to enhance neurosurgery workflows by reducing procedure times in MRI and Operating Room settings. The Array system's flexibility is expected to increase accessibility for hospitals and surgeons. Initial procedures were conducted by prominent neurosurgeons at renowned institutions, showcasing the system's efficiency. Full market release of the Array is anticipated in early 2022, following a phase of limited market release to gather training materials and case studies.
ClearPoint Neuro reported Q1 2021 revenue of $4.0 million, up 29% year-over-year. Biologics and drug delivery revenue surged 61% to $1.7 million. The company added new partnerships, raising its total to approximately 30. Case volume increased to 214, exceeding previous estimates. Following a public offering, net proceeds reached $46.8 million, bolstering cash reserves to nearly $65.0 million. Despite hospital budget constraints, the company anticipates 2021 revenues between $16.0 million and $17.5 million.
ClearPoint Neuro (Nasdaq: CLPT) announced a partnership with D&K Engineering to develop a robotic system for MRI and operating room use. This collaboration aims to streamline neurosurgery, enhancing procedural efficiency and patient interaction. The partnership leverages ClearPoint's existing technology and D&K's expertise in medical devices. The robotic system is expected to see its first clinical application in 2023. ClearPoint Neuro's platform has FDA clearance and is already implemented in over 60 clinical sites across the U.S., Canada, and Europe.
ClearPoint Neuro (Nasdaq: CLPT) announced its Q1 2021 financial results release date set for May 11, 2021, after market close. The live broadcast for the results will occur at 4:30 PM ET on the same day. Interested parties can access the call online or by phone. ClearPoint Neuro focuses on improving patient quality of life through precise therapies for neurological disorders, with FDA-cleared products used in over 60 clinical sites. The company’s partnerships include 25 biologics and drug delivery companies, supporting over 4,000 cases.
ClearPoint Neuro (CLPT) announced its support for Voyager Therapeutics' FDA clearance of the IND application for the gene therapy candidate VY-HTT01, aimed at treating Huntington’s disease, affecting around 30,000 people in the U.S. This gene therapy will undergo a Phase 1/2 clinical trial to assess its safety and tolerability. ClearPoint's navigation and delivery systems play a crucial role in this trial. The company remains committed to innovating and providing clinical services that support complex neurological treatments.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced on April 23, 2021, that its Board of Directors approved the grant of stock options and restricted shares to Mr. Danilo D’Alessandro. The package includes 30,000 restricted shares and a stock option for 75,000 shares at an exercise price of $5.80, with vesting starting September 29, 2021. This grant follows NASDAQ guidelines and aims to facilitate Mr. D’Alessandro's acceptance of employment. The company focuses on enabling advanced therapies for neurological disorders through its FDA-cleared products.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced the upcoming retirement of John N. Spencer, Jr. from its Board of Directors, effective at the Annual Meeting of Stockholders on June 3, 2021. Spencer has served since March 2010 and is credited with substantially contributing to the company's growth. ClearPoint has achieved significant milestones, including nearing its 5,000th case, and holds a preeminent status in the medical device sector. The company provides innovative solutions for neurological disorders.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announces that uniQure N.V. has completed patient enrollment for the first dose cohort of a randomized Phase I/II clinical trial of AMT-130 for early-stage Huntington's disease. Six of ten patients received AMT-130 using ClearPoint's navigation systems. A second cohort with 16 patients is set to enroll in late 2021, along with a Phase Ib/II trial planned in Europe. Huntington's disease affects ~70,000 individuals in the U.S. and Europe, with no approved therapies currently available for its progression.
ClearPoint Neuro (CLPT) announced the appointment of Ellisa Cholapranee as General Counsel, effective April 5, 2021. Reporting to CEO Joe Burnett, Cholapranee brings nearly a decade of legal experience in the life sciences and medical device sectors. Her expertise in compliance, strategy, and partnerships is expected to enhance the company's operations, especially in gene therapy and drug delivery agreements. The company continues to innovate in neurological disorder treatments, with its ClearPoint Neuro Navigation System already installed in over 60 clinical sites.
ClearPoint Neuro reports a 16% revenue increase to $3.7 million in Q4 2020, with full-year revenues totaling $12.8 million, up 14% from 2019. Notably, biologics and drug delivery revenues surged by 109% to $5.0 million, while functional neurosurgery revenues declined by 12% to $6.3 million due to COVID-19 challenges. The company's gross margin improved to 71%, attributed to higher service revenue. Despite a solid year, ClearPoint refrains from forecasting for 2021, citing persistent COVID-related disruptions in elective procedure volumes.